Protavio recently had the opportunity to present at the Olink Proteomics World virtual conference on September 26th, where we unveiled our cutting-edge work in collaboration with Hamilton Robotics. Our digital poster, titled “Automated Platform for the Discovery of Novel Biomarkers for Early Cancer Detection Using Olink Technology“ highlighted an innovative automated pipeline for protein biomarker discovery that leverages the Olink Explore platform and Hamilton Robotics’ advanced automation systems.
The core of our work integrates the Olink Explore platform with advanced bioinformatics and Hamilton Robotics’ Microlab STAR system, pushing the boundaries of what’s possible in proteomics. Our poster presented results from the Olink Concordance Test, which compared data quality between Protavio and AS Uppsala. Our automated system performed exceptionally well, meeting all key criteria such as detectability, coefficient of variance, and correlation, showcasing its robust capabilities. We also showcased results of a feasibility study conducted as part of the DIOPTRA, an EU project aligned with the Mission on Cancer initiative (Grant Agreement #101096649). Through this study, we explored the platform’s potential in early colorectal cancer (CRC) detection. Using plasma samples from CRC patients, individuals with advanced adenomas, and those with no colonoscopy findings, we identified significant differential protein expression, offering promising leads for early cancer biomarkers.
This collaboration underscores Protavio’s dedication to pioneering biomarker discovery and advancing the development of more effective diagnostic tools for early cancer detection. We look forward to the continued impact of these technologies to shape the future of proteomics and enhance patient outcomes.
Stay tuned for more updates on our pioneering work!